{
    "2020-11-02": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Novartis Expands Presence in Gene Therapy With Acquisition",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Expands",
                        "Gene Therapy",
                        "Acquisition"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "Top Analyst Reports for PayPal, Comcast & Novartis",
                "features": {
                    "keywords": [
                        "Analyst Reports",
                        "PayPal",
                        "Comcast",
                        "Novartis"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "technology",
                        "media"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Analyst Report: Novartis AG",
                "features": {
                    "keywords": [
                        "Analyst Report",
                        "Novartis AG"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "Eli Lilly",
                        "Merck",
                        "Pfizer",
                        "Novartis",
                        "AstraZeneca",
                        "J&J"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Novartis announces positive results from a Phase IV study showing superior tolerability and efficacy of AimovigÂ® (erenumab) compared with topiramate in migraine prevention",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Phase IV",
                        "Aimovig",
                        "erenumab",
                        "topiramate",
                        "migraine prevention"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}